Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
Saved in:
| Main Authors: | Fernanda Faião-Flores, Keiran SM Smalley |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-12-01
|
| Series: | Melanoma Management |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/mmt-2019-0017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat
by: Tamara Zenz, et al.
Published: (2025-02-01) -
Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility
by: Jonas K. Oddershede, et al.
Published: (2025-04-01) -
Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinib
by: André Schreiber, et al.
Published: (2025-12-01) -
Ferrocene Derivatives as Histone Deacetylase Inhibitors: Synthesis and Biological Evaluation
by: Rostislava Angelova, et al.
Published: (2025-01-01) -
Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases
by: Maria A. Theodoropoulou, et al.
Published: (2024-12-01)